4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
Top Page
4DMedical Ltd
(Sydney:4DX)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$4.50
â–¼(-22.95% Downside)
Action:Reiterated
Date:06/20/26
The score is held back primarily by weak financial performance (declining revenue, persistent losses, and negative cash flows). Technicals provide partial support with price above key moving averages, but momentum signals are mixed. Valuation remains constrained by negative earnings and no provided dividend yield.
Positive Factors
Proprietary XV imaging tech
4DMedical’s XV CT-based lung ventilation analytics is a proprietary clinical platform sold to healthcare providers. This differentiated technology creates clinical integration barriers and recurring use potential, supporting durable adoption and specialty-market positioning over time.
Negative Factors
Declining revenue
A shrinking top line (-6.1%) signals weakening commercial traction and slows the path to scale. Prolonged revenue contraction reduces ability to absorb fixed costs, lengthens time to profitability, and undermines returns on product development and sales investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary XV imaging tech
4DMedical’s XV CT-based lung ventilation analytics is a proprietary clinical platform sold to healthcare providers. This differentiated technology creates clinical integration barriers and recurring use potential, supporting durable adoption and specialty-market positioning over time.
Read all positive factors
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.81B
Dividend YieldN/A
Average Volume (3M)10.77M
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue Growth-0.80%
EPS Growth-249.48%
CountryAU
Employees145
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,361,300
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.37
Revenue Forecast (FY)AU$7.00M
4DMedical Ltd Business Overview & Revenue Model
Company Description
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, a...
How the Company Makes Money
null...
4DMedical Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.33M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | -17.18M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -35.46M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -159.59M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 139.55M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 56.76M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 6.42M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 167.95M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | -28.40M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -22.99M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -22.82M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 75.41M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
Positive
5.84
Price Trends
4.22
Positive
4.28
Positive
3.34
Positive
Market Momentum
0.06
Negative
65.39
Neutral
80.47
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Positive. The current price of 5.84 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 4.22, and above the 200-day MA of 3.34, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 65.39 is Neutral, neither overbought nor oversold. The STOCH value of 80.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:4DX.
4DMedical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$209.27M | 59.00 | 4.20% | ― | 19.23% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$2.81B | -14.63 | -890.76% | ― | -0.80% | -249.48% | |
45 Neutral | AU$21.96M | -0.50 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$144.08M | -13.28 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$66.81M | -3.45 | -54.48% | ― | 17.24% | -20.00% | |
40 Underperform | AU$26.98M | -1.88 | -180.06% | ― | 74.74% | 4.32% |
* Healthcare Sector Average
AU:4DX
4DMedical Ltd
4.73
4.48
1792.00%
AU:IPD
Impedimed Limited
0.01
-0.02
-54.84%
AU:CYC
Cyclopharm Limited
0.55
-0.38
-41.08%
AU:MX1
Micro-X Ltd.
0.04
-0.02
-30.00%
AU:ARX
Aroa Biosurgery Ltd
0.60
0.09
17.65%
AU:EMV
EMvision Medical Devices Ltd.
1.56
-0.22
-12.36%
4DMedical Ltd Corporate Events
4DMedical launches CLEAR program to push CT:VQ into US$3bn pulmonary embolism market
Jun 1, 2026
4DMedical has launched CLEAR, a clinical evidence program designed to accelerate the adoption of its contrast-free CT:VQ technology in the acute pulmonary embolism market. By extending beyond the traditional nuclear VQ segment into the much larger...
4DMedical Plans Modest Share Issue to Support Growth
Jun 1, 2026
4DMedical Ltd has outlined plans for a new issue of ordinary fully paid shares on the ASX, signalling a modest capital raise through a placement or similar structure. The company has notified the exchange of a maximum of 56,235 new securities to b...
4DMedical buys contextflow to fast-track European lung imaging push
Jun 1, 2026
4DMedical has moved to establish a major European presence by agreeing to acquire Austrian lung imaging specialist contextflow, securing an immediate commercial and clinical platform across the region. The deal gives the company a Vienna-based tea...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
May 29, 2026
4DMedical Ltd has applied for quotation on the ASX of a small parcel of new ordinary fully paid shares, totaling 92,740 securities issued on May 25 and May 29, 2026. The additional shares, arising from the exercise or conversion of existing option...
4DMedical Secures U.S. Outpatient Rollout for CT:VQ via SimonMed Deal
May 29, 2026
4DMedical has signed a three-year commercial agreement with SimonMed Imaging, one of the largest physician-led outpatient imaging providers in the U.S., to deploy its CT:VQ and LDAf quantitative cardiopulmonary analysis tools across SimonMed’...
Citi Group Entities Cease to Be Substantial Holder in 4DMedical
May 26, 2026
Citigroup Global Markets Australia and related Citi entities have notified 4DMedical that they have ceased to be a substantial holder in the company as of 22 May 2026. The change follows a series of adjustments in relevant interests across multipl...
State Street Group Ceases to Be Substantial Holder in 4DMedical
May 4, 2026
State Street Corporation and several of its asset management subsidiaries, including State Street Global Advisors entities in Australia, Europe and the U.S., have disclosed that they have ceased to be substantial shareholders in 4DMedical Ltd. The...
4DMedical Seeks ASX Quotation for 2.16 Million New Shares
May 1, 2026
4DMedical Ltd has applied to the ASX for quotation of new ordinary fully paid shares following the conversion of options or other convertible securities. The application covers a total of 2,159,719 shares issued across three dates in April and May...
4DMedical accelerates global rollout of CT:VQ on surging scan volumes and fresh capital
Apr 30, 2026
4DMedical reported strong third-quarter momentum as it deepens penetration of leading U.S. academic medical centres with its CT:VQ lung imaging platform, adding a commercial contract with University of Chicago Medicine and a 90-day evaluation at M...
4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance
Apr 17, 2026
4DMedical Limited has issued 162,045 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share capital without a formal prospectus disclosure. The company confirmed it is compliant with ke...
4DMedical Seeks ASX Quotation for Additional 1.2 Million Shares
Apr 17, 2026
4DMedical Limited has applied to the ASX for quotation of an additional 1,206,912 ordinary fully paid shares, issued on 10 April and 17 April 2026, under its ticker 4DX. The new securities arise from the exercise or conversion of existing options ...
4DMedical to Join S&P/ASX 200 as Insignia Financial Exits
Apr 13, 2026
SP Dow Jones Indices will remove Insignia Financial Limited from the SP/ASX 200 Index following its proposed acquisition by Daintree BidCo Pty Ltd, with the change scheduled to take effect before trading opens on 20 April 2026. 4DMedical Limited w...
4DMedical Seeks ASX Quotation for 938,175 Newly Issued Shares
Apr 2, 2026
4DMedical Ltd has applied for quotation on the ASX of a total of 938,175 new fully paid ordinary shares, issued in two tranches on 27 March 2026 and 2 April 2026. The additional shares, arising from the exercise or conversion of existing options o...
4DMedical Issues Over 14 Million New Shares and Confirms Regulatory Compliance
Apr 1, 2026
4DMedical has issued 14,067,797 fully paid ordinary shares, in line with prior announcements, and confirmed that the shares were issued without the need for a disclosure document under the Corporations Act. The company stated it remains compliant ...
4DMedical Seeks ASX Quotation for 14 Million New Shares
Apr 1, 2026
4DMedical Ltd has applied for quotation on the ASX of 14,067,797 new ordinary fully paid shares, with an issue date of 2 April 2026. The additional securities, previously flagged in an Appendix 3B, will increase the company’s free float and ...
4DMedical plans new share issue to fund growth
Mar 26, 2026
4DMedical Ltd, an ASX-listed medtech company specialising in lung imaging and respiratory diagnostic technologies, continues to build its capital base to support its commercial and development activities. The company operates under the ticker 4DX ...
4DMedical wins EU approval for CT:VQ and raises $83m to drive expansion
Mar 26, 2026
4DMedical has secured CE Mark certification for its CT:VQ™ ventilation-perfusion imaging technology, clearing the way for commercial deployment across the European Union, one of the world’s largest markets for cardiothoracic imaging. T...
4DMedical wins Mayo Clinic deployment in push to make CT:VQ lung imaging standard of care
Mar 24, 2026
4DMedical has secured deployment of its CT:VQ ventilation-perfusion imaging technology at Mayo Clinic, the top-ranked U.S. hospital, marking a major endorsement of its platform by one of the most influential healthcare institutions globally. The i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.